Bone drug switch: can alendronate and zoledronate keep bones strong after denosumab?
NCT ID NCT05091099
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the best way to prevent bone loss after stopping denosumab, a common osteoporosis treatment. Researchers tested giving alendronate first, then zoledronate, versus zoledronate alone in 44 postmenopausal women and men over 50. The goal was to see which approach better maintains bone density and reduces fracture risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alendronate and zoledronate (bisphosphonate drugs)
What this could lead to
If it works, this could provide a clear treatment plan to maintain bone strength after stopping denosumab, reducing fracture risk.
What could go wrong
This is a small, single-center study with only 44 participants, so results may not apply to everyone. The drugs may not fully prevent bone loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital, Yunlin branch
Douliu, Yunlin County, 640, Taiwan